S27 Sustained anti-inflammatory effects of lumacaftor-Ivacaftor in sputum and peripheral blood samples of adult cystic fibrosis patients- an observational study

• Published in: Thorax Vol. 77; no. Suppl 1; pp. A20 - A21
• Main Authors: Arooj, P, Morrissy, D, Ronan, N, McCarthy, Y, Fleming, C, Eustace, JA, Murphy, DM, Plant, BJ
• Format: Journal Article
• Language: English
• Published: London BMJ Publishing Group Ltd and British Thoracic Society 11.11.2022; BMJ Publishing Group LTD
• Subjects: Anti-inflammatory agents; Antibiotics; Clinical outcomes; Cystic fibrosis; Cytokines; Inflammation; Mutation; Observational studies; Patients; Plasma; ‘Transformers’ – Transformational treatments and technologies in CF
• ISSN: 0040-6376; 1468-3296
• DOI: 10.1136/thorax-2022-BTSabstracts.33

IntroductionPrevious studies showed that the combination of CFTR corrector and potentiator, lumacaftor-ivacaftor (LUMA-IVA) provides meaningful clinical benefits in patients with cystic fibrosis (PWCF) who are homozygous for the Phe508del CFTR mutation. However, little is known about the effect of LUMA-IVA on proinflammatory cytokines (PICs). We sought to investigate the impact of lumacaftor-ivacaftor CFTR modulation on circulatory and airway cytokines before and after 12 months of lumacaftor-ivacaftor treatment in a real world setting.MethodsIn this study, we assessed both plasma and sputum proinflammatory cytokines, as well as standard clinical outcomes including FEV1%, BMI, sweat chloride and pulmonary exacerbations at baseline and prospectively for one-year post commencement of LUMA-IVA in forty -four patients with CF aged sixteen years and older with homozygous for the Phe508del CFTR mutation.ResultsSignificant reduction in plasma IL-8 (p<0.001), TNF-α (p<0.001), IL-1ß (p<0.001) levels and in sputum IL-6 (p<0.05), IL-8 (p<0.01) and TNF-α (p<0.001) levels were observed after lumacaftor -ivacaftor therapy. Clinically significant improvements in FEV1% predicted (mean +3.38%, p=0.002), BMI (mean +0.8 kg/m2, p<0.001), sweat chloride (mean -19 mmol/l, p<0.001), as well as in intravenous antibiotics usage (mean -0.70, p<0.001) and hospitalization (mean-0.38, p=0.002) were observed after initiation of lumacaftor-ivacaftor therapy.ConclusionsThis real -world study demonstrates that lumacaftor-ivacaftor has significant and sustained beneficial effects on both circulatory and airway inflammation. Our findings show that lumacaftor-ivacaftor results in anti-inflammatory changes in addition to its ability to stimulate CFTR function, which could contribute to improve standard clinical outcomes.